ATE330017T1 - Kallikrein gen - Google Patents

Kallikrein gen

Info

Publication number
ATE330017T1
ATE330017T1 AT01966837T AT01966837T ATE330017T1 AT E330017 T1 ATE330017 T1 AT E330017T1 AT 01966837 T AT01966837 T AT 01966837T AT 01966837 T AT01966837 T AT 01966837T AT E330017 T1 ATE330017 T1 AT E330017T1
Authority
AT
Austria
Prior art keywords
kallikrein
gen
protein
compositions
relates
Prior art date
Application number
AT01966837T
Other languages
German (de)
English (en)
Inventor
George M Yousef
Eleftherios P Diamandis
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Application granted granted Critical
Publication of ATE330017T1 publication Critical patent/ATE330017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01966837T 2000-08-11 2001-08-10 Kallikrein gen ATE330017T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22485300P 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
ATE330017T1 true ATE330017T1 (de) 2006-07-15

Family

ID=22842508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966837T ATE330017T1 (de) 2000-08-11 2001-08-10 Kallikrein gen

Country Status (9)

Country Link
US (2) US7199229B2 (enExample)
EP (1) EP1309703B1 (enExample)
JP (1) JP2004505649A (enExample)
AT (1) ATE330017T1 (enExample)
AU (2) AU8738401A (enExample)
CA (1) CA2418422C (enExample)
DE (1) DE60120712T2 (enExample)
ES (1) ES2266245T3 (enExample)
WO (1) WO2002014485A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7199229B2 (en) * 2000-08-11 2007-04-03 Mount Sinai Hospital Kallikrein gene
AU2002213704A1 (en) * 2000-10-27 2002-05-06 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (HK6)
CA2426571A1 (en) * 2000-11-01 2002-05-10 Eleftherios P. Diamandis Detection of ovarian cancer
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
AU2003269618A1 (en) * 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
WO2004021009A2 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
AU2003271456A1 (en) * 2002-09-26 2004-04-19 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
US20060141471A1 (en) * 2003-02-27 2006-06-29 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1711616A1 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 15 (klk15)
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
AU2001271427A1 (en) * 2000-06-26 2002-01-08 Sugen, Inc. Novel proteases
CA2416691A1 (en) * 2000-07-21 2002-01-31 Incyte Genomics, Inc. Proteases
US7199229B2 (en) 2000-08-11 2007-04-03 Mount Sinai Hospital Kallikrein gene
AU2002213704A1 (en) * 2000-10-27 2002-05-06 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (HK6)
US6962793B2 (en) 2000-10-27 2005-11-08 Mount Sinai Hospital Methods for detecting Alzheimers disease
CA2426571A1 (en) * 2000-11-01 2002-05-10 Eleftherios P. Diamandis Detection of ovarian cancer
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
CA2481093A1 (en) 2002-04-04 2003-10-16 Mount Sinai Hospital Methods for detecting ovarian cancer
WO2004021009A2 (en) 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
AU2003269618A1 (en) 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
AU2003271456A1 (en) 2002-09-26 2004-04-19 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
US20060141471A1 (en) 2003-02-27 2006-06-29 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Also Published As

Publication number Publication date
US20040058342A1 (en) 2004-03-25
JP2004505649A (ja) 2004-02-26
ES2266245T3 (es) 2007-03-01
CA2418422C (en) 2011-06-07
WO2002014485A3 (en) 2003-01-09
CA2418422A1 (en) 2002-02-21
DE60120712T2 (de) 2007-07-19
US20070178114A1 (en) 2007-08-02
DE60120712D1 (en) 2006-07-27
EP1309703B1 (en) 2006-06-14
EP1309703A2 (en) 2003-05-14
US7507403B2 (en) 2009-03-24
US7199229B2 (en) 2007-04-03
AU8738401A (en) 2002-02-25
AU2001287384B2 (en) 2007-03-29
WO2002014485A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
ATE330017T1 (de) Kallikrein gen
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
BR0110375B1 (pt) compressor.
ITTO20000779A0 (it) Composizioni farmaceutiche.
ATE380194T1 (de) 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-
MX242679B (es) Antranilamidas insecticidas.
BR0215405A (pt) Composições e processos de uso de collajolie
MA25758A1 (fr) Inhibiteurs de protease.
MXPA03001801A (es) Composicion acondicionadora pre-champu.
ITTO20020744A1 (it) Composizione.
DZ3441A1 (fr) Nouvelles phenylpiperazines.
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
MXPA03001857A (es) Composicones medicinales.
ITTO20020745A1 (it) Composizione.
ES1048400Y (es) Bota-patin mejorada.
DE60102704D1 (de) Trioxepan verbindungen
ES1047015Y (es) Manometro.
IT1319677B1 (it) Composizione funghicida.
ITTO20020746A1 (it) Composizione.
ES1057516Y (es) Pieza rodapie mejorada.
TW200500081A (en) Novel rotaviruses and use thereof
ES1048930Y (es) Tijera primeros meses.
DK1204687T3 (da) Silan-endeafsluttende, fugtighedshærdelige sammensætninger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties